Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses
European Endocrinology · 2022 · 18 (2) · 96
DOI: 10.17925/ee.2022.18.2.96 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Endocrinology, 2022. Verfasst von Harmanjit Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This article is published under the Creative Commons Attribution Non-commercial License..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Statin use has been linked with new-onset diabetes mellitus (NODM). In the present systematic review, we aimed to determine the incidence of NODM with statin use by assessing and summarizing the data generated by different systematic reviews and metaanalyses published on this topic. We conducted a systematic review of systematic reviews and meta-analyses using a pre-defined study protocol. Two authors independently performed a literature search using PubMed, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) for studies reporting data on statin use and NODM incidence and screened and extracted data for the outcomes of interest. The Assessing the Methodological Auality of Systematic Reviews 2 (AMSTAR 2) checklist was used to evaluate the quality of the included systematic reviews and meta-analyses. The initial search yielded 621 potential records, and 16 relevant systematic reviews and meta-analyses were included in the present systematic review. The included studies showed an increase in the risk of NODM with statin use. In particular, rosuvastatin and atorvastatin were associated with NODM in many systematic reviews or meta-analyses; however, pravastatin and pitavastatin were found to be associated with lower or no risk. We observed a positive trend of development of NODM with statin use became more evident with advancing years as more number of studies were added. Intensive doses of statins and use in older subjects were found to be important risk factors for NODM. Finally, the quality assessment revealed that the included systematic reviews and metaanalyses were of critically low or low quality. We concluded that statin use carries a risk of causing NODM. Statins should not be discouraged in anticipation of NODM. However, glycaemic monitoring should be encouraged with the on-going statin therapy. Furthermore, clinical studies addressing the use of statins and the incidence of NODM as their primary objective should be planned.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India.
- These authors have contributed equally to this work and share first authorship.
- MBBS Student, Government Medical College and Hospital, Chandigarh, India.
- Department of Neonatology, Government Medical College and Hospital, Chandigarh, India.
- Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
Förderung
- This article is published under the Creative Commons Attribution Non-commercial License.
Zitieren
APA
Singh, H., Sikarwar, P., Khurana, S., & Sharma, J. (2022). Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses. European Endocrinology, 18(2), 96. https://doi.org/10.17925/ee.2022.18.2.96
Vancouver
Singh H, Sikarwar P, Khurana S, Sharma J. Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses. European Endocrinology. 2022;18(2):96. doi:10.17925/ee.2022.18.2.96
BibTeX
@article{Singh2022,
author = {Singh, Harmanjit and Sikarwar, Pallavi and Khurana, Supreet and Sharma, Jatin},
title = {Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses},
journal = {European Endocrinology},
year = {2022},
volume = {18},
number = {2},
pages = {96},
doi = {10.17925/ee.2022.18.2.96}
}
EUVIMED